Key Takeaways:
(Bloomberg) -- Aardvark Therapeutics Inc. (NASDAQ: AARD) shares plunged 56% on March 2 after the company announced a halt to its pivotal Phase 3 trial for its lead drug candidate, ARD-101, prompting a law firm investigation.
"The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws," the firm said in a statement on April 22.
The stock dropped $7.02 to close at $5.51 on March 2, its largest single-day decline since its IPO. The halt centered on the HERO (Hunger Elimination of Reduction Objective) trial, which was assessing ARD-101 for treating hyperphagia, or insatiable hunger, in patients with Prader-Willi Syndrome (PWS).
The sudden halt of a late-stage trial for its primary drug candidate raises significant questions about the future of Aardvark's pipeline and its commercial prospects. The investigation by Hagens Berman introduces legal and financial risks for the company, which could face a class-action lawsuit from investors who suffered losses.
The decline puts the stock at its lowest since its public debut, erasing over half of the company's market capitalization in a single session. Investors will be closely watching for Aardvark's official response to the investigation and any further details on the reasons for the trial's cessation.
This article is for informational purposes only and does not constitute investment advice.
